Fernández-del Castillo AC

Language: Spanish
References: 20
Page: 481-487
PDF size: 71.45 Kb.

Text Extraction

No Abstract

REFERENCES

1. Howard JM, Hess W. History of the pancreas: mysteries of a hidden organ. New York: Kluger Academic/Plenum Publishers; 2002.

2. Whipple AO. Hyperinsulinism in relation to pancreatic tumors. Surgery 1944; 16: 289-305.

3. Frantz VK. Tumors of islet cells with hyperinsulinism. Benign, malignant and questionable. Ann Surg 1940; 112: 161-76.

4. 4 Deveny CW. Islet cell tumors: an overview. In: Beger H, Warshaw AL, Buchler M, Carr-Locke DL, Neoptolemos JP, Rusell CG, et al. (eds.). The Pancreas. Blackwell Science; 1998, p. 1183-6.

5. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Current Opinion in Oncology 2000; 12: 368-77.

6. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt H, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998; 2: 473-82.

7. Pelley RJ, Bukowski RM. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Current Opinion in Oncology 1999; 11: 32-7.

8. Chu QD, Hill HC, Douglass HO, Driscoll D, Smith JL, Nava HR, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855-62.

9. Solorzano CC, Lee JE, Pisters PW, Vauthery JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078-85.

10. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv 1995; 425: 547-60.

11. Heymann MF, Joubert M, Nemeth J, Franc B, Visset J, Hamy A, et al. Prognostic and immunhistochemical validation of the Capella classification of pancreatic neuroendocrine tumors: an analysis of 82 sporadic cases. Histopathology 2000; 36: 421-32.

12. Hochwald SN, Zee SY, Conlon KC, Colleoni R, Louie O, Brennan M, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20: 2633-42.

13. Deshpande V, Fernández-del Castillo C, Muzikansky A, Deshpande A, Zuckerberg L, Warshaw AL, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 2004; 28: 1145-53.

14. Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg 2000; 24: 1312-18.

15. Broughan TA, Leslie JD, Soto JM. Pancreatic islet cell tumors. Surgery 1986; 99: 671-8.

16. White TJ, Edney JA, Thompson JS, Karrer FW, Moor BJ. Is there a prongostic difference between functional and nonfunctional islet cell tumors? Am J Surg 1994; 168: 627-30.

17. Wick MR, Graeme-Cook F. Pancreatic Neuroendocrine Neoplasms: a current summary of diagnostic, prognostic, and differenctial diagnostic information. Am J Clin Pathol 2001; 115: S28-S45.

18. Gentil Perret A, Mosnier JF, Buono JP. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 1998; 109: 286-93.

19. Bouwens L, Lu WG, De Krijer R. Proliferation and differentiation in the human fetal endocrine pancreas. Diabetología 1997; 40: 398-404.

20. Deshpande V, Selig MK, Gunnlaugur PN, Fernández-del Castillo C, Lauwers GY. Ductulo-insular pancreatic endocrine neooplasms: clinicopathologic analysis of a unique subtype of pancreatic endocrine neoplasms. Am J Surg Pathol 2003; 27: 461-8.